Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 10, 1997, Pages 2159-2164

  Patick, A K ^a   Boritzki, T J ^a   Bloom, L A ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

EID: 0030812875     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.10.2159     Document Type: Article

References (34)

1. Alley, M. C., D. A. Scudiero, A. Monks, M. L. Hursey, M. J. Czerwinski, D. L. Fine, B. J. Abbott, J. G. Mayo, R. H. Shoemaker, and M. R. Boyd. 1988. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601.
2. Carter, W. H., and G. L. Wampler. 1986. Review of the application of response surface methodology in the combination therapy of cancer. Cancer Treatment Rep. 70:133-140.
3. Cohen, C., E. Sun, W. Cameron, D. McMahon, C. Farthing, D. Poretz, M. Markowitz, S. Follansbee, J. Mellors, D. Ho, A. Hsu, R. Maki, M. Salgo, and J. Leonard. 1996. Ritonavir-saquinavir combination treatment in HIV-infected patients, abstr. LB7b, p. 8. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Addendum. American Society for Microbiology, Washington, D.C.
4. Conant, M., M. Markowitz, A. Hurley, D. Ho, J. Peterkin, and S. Chapman. 1996. A randomized phase II dose range-finding study of the HIV protease inhibitor VIRACEPT® as monotherapy in HIV positive patients, abstr. Tu.B.2129. In Abstracts of the XI International Conference on AIDS.
5. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
6. Craig, J. C., L. Whittaker, I. B. Duncan, and N. A. Roberts. 1994. In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV proteinase inhibitor saquinavir (Ro 31-8959). Antivir. Chem. Chemother. 5:380-386.
7. Deminie, C. A., C. M. Bechtold, D. Stock, M. Alam, F. Djang, A. H. Balch, T.-C. Chou, M. Prichard, R. J. Colonno, and P.-F. Lin. 1996. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob. Agents Chemother. 40:1346-1351.
8. Eron, J. J., Jr., V. A. Johnson, D. P. Merrill, T.-C. Chou, and M. S. Hirsch. 1992. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob. Agents Chemother. 36:1559-1562.
9. Gathe, J., Jr., B. Burkhardt, P. Hawley, M. Conant, J. Peterkin, and S. Chapman. 1996. A randomized phase II study of VIRACEPT®, a novel HIV protease inhibitor, used in combination with stavudine vs. stavudine alone, abstr. Mo.B.413. In Abstracts of the XI International Conference on AIDS.
10. Gaumont, Y., R. L. Kisliuk, J. C. Parsons, and W. R. Greco. 1992. Quantitation of folic acid enhancement of antifolate synergism. Cancer Res. 52: 2228-2235.
11. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharm. Rev. 47:331-385.
12. Henry, K., A. Lamarca, R. Myers, and S. Chapman. 1996. A randomized phase II study of VIRACEPT®, a novel HIV protease inhibitor, used in combination with stavudine vs. stavudine alone, abstr. Mo.B.413. In Abstracts of the XI International Conference on AIDS.
13. Jackson, R. C. 1992. The theoretical foundations of cancer chemotherapy introduced by computer models. Academic Press, Inc., San Diego, Calif.
14. Jacobsen, H., M. Hänggi, M. Ott, I. B. Duncan, S. Owen, M. Andreoni, S. Vella, and J. Mous. 1996. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. J. Infect. Dis. 173:1379-1387.
15. Johnson, V. A., D. P. Merrill, J. A. Videler, T.-C. Chou, R. E. Byington, J. J. Eron, R. T. D'Aquila, and M. S. Hirsch. 1991. Two-drug combination of zidovudine, didanosine, and recombinant interferon-α A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J. Infect. Dis. 164:646-655.
16. Johnson, V. A., D. P. Merrill, T.-C. Chou, and M. S. Hirsch. 1992. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-α A against zidovudine-sensitive or -resistant HIV-1 in vitro. J. Infect. Dis. 166:1143-1146.
17. Johnson, V. A., M. A. Barlow, D. P. Merrill, T.-C. Chou, and M. S. Hirsch. 1990. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J. Infect. Dis. 161:1059-1067.
18. Kravcik, S., J. Sahai, B. Kerr, R. Anderson, N. Buss, I. Seguin, N. Bristow, A. Farnsworth, M. Salgo, P. Mastrodonato-Delora, and W. Cameron. 1997. Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV+ patients, abstr. 371. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
19. Krogstad P., B. Kerr, R. Anderson, A. Hendricks, K. Luzuriaga, A. Wiznia, and Y. Bryson. 1997. Phase I study of the HIV-protease inhibitor nelfinavir mesylate (NFV) in HIV+ children, abstr. 721. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
20. Lambert, D. M., H. Bartus, A. V. Fernandez, C. Bratby-Anders, J. J. Leary, G. B. Dreyer, B. W. Metcalf, and S. R. Petteway, Jr. 1993. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection. Antiviral Res. 21:327-342.
21. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
22. Manion, D. J., D. P. Merrill, T.-C. Chou, and M. S. Hirsch. 1996. Susceptibility of multidrug resistant HIV-1 to combination drug regimens in vitro, abstr. II, p. 186. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
23. Markowitz, M., Y. Cao, A. Hurley, R. O'Donovan, J. Peterkin, B. Anderson, L. Smiley, A. Keller, P. Johnson, D. Johnson, and D. D. Ho. 1996. Triple therapy with AZT and 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naive subjects chronically infected with HIV-1, abstr. LB.B.6031. In Abstracts of the XI International Conference on AIDS.
24. Mascolini, M. 1996. Outing HIV. J. Int. Assoc. Physicians AIDS Care 2:29-56.
25. Merrill, D. P., M. Moonis, T.-C. Chou, and M. S. Hirsch. 1996. Lamivudine or stavudine in two-and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J. Infect. Dis. 173:355-364.
26. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 2:760-766.
27. Pagano, P. J., and K.-T. Chong. 1995. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-α J. Infect. Dis. 171:61-67.
28. Patick, A. K., M. Duran, Y. Cao, T. Ho, Z. Pei, M. R. Keller, et al. 1996. Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir. Antiviral Ther. 1(Suppl. 1):17. (Abstract 29.)
29. Patick, A. K., H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, and S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297.
30. Powderly, W., M. Sension, M. Conant, A. Stein, and N. Clendeninn. 1997. The efficacy of VIRACEPT® (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC, abstr. 370. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
31. Prichard, M. N., K. R. Aseltine, and C. Shipman. 1992. MacSynergy II (version 1.0) user's manual. University of Michigan, Ann Arbor.
32. Prichard, M. N., and C. Shipman. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-206.
33. Sørensen, A. M., C. Nielsen, L. R. Mathiesen, J. O. Nielsen, and J.-E. S. Hansen. 1993. Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scand. J. Infect. Dis. 25:365-371.
34. Taylor, D. L., T. M. Brennan, C. G. Bridges, M. S. Kang, and A. S. Tyms. 1995. Synergistic inhibition of human immunodeficiency virus type 1 in vitro by 6-O-butanoylcastanospermine (MDL 28 574) in combination with inhibitors of the virus-encoded reverse transcriptase and proteinase. Antivir. Chem. Chemother. 6:143-152.